References
- Mead AJ, Chowdhury O, Pecquet C, et al. Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood. 2013;121(20):4156–4165.
- Rumi E, Harutyunyan AS, Casetti I, et al. A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol. 2014;89(1):117–118.
- Mead AJ, Rugless MJ, Jacobsen SEW, et al. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967–969.
- Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am. 2012;26(5):1037–1051.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Park S, Ha JS. Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population. Int J Lab Hematol. 2015;37(4):e91–e95.
- Campbell PJ. Somatic and germline genetics at the JAK2 locus. Nat Genet. 2009;41(4):385–386.
- Jones AV, Cross NC. Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol. 2013;4(4):237–253.
- Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367–374.
- De Filippi P, Zecca M, Lisini D, et al. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol. 2009;147(5):706–709.
- Doisaki S, Muramatsu H, Shimada A, et al. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Blood. 2012;120(7):1485–1488.
- Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628–1632.